Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer
Authors
Keywords
-
Journal
CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-09-04
DOI
10.1002/cncr.32445
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
- (2018) Emelia J. Benjamin et al. CIRCULATION
- The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II)
- (2017) E. David Crawford et al. UROLOGY
- Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial
- (2016) Emmanuel S. Antonarakis et al. CLINICAL CANCER RESEARCH
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
- (2016) Douglas G. McNeel et al. Journal for ImmunoTherapy of Cancer
- Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) C. Parker et al. ANNALS OF ONCOLOGY
- A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
- (2015) E. J. Small et al. CLINICAL CANCER RESEARCH
- Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline
- (2014) Ethan Basch et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer
- (2014) Susan Halabi et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial
- (2013) Paul F. Schellhammer et al. UROLOGY
- Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
- (2012) Nadeem A. Sheikh et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer
- (2011) T. M. Beer et al. CLINICAL CANCER RESEARCH
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- Definition and Evaluation of Transient Ischemic Attack
- (2009) J. Donald Easton et al. STROKE
- CD54 is a surrogate marker of antigen presenting cell activation
- (2008) N. A. Sheikh et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now